Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Kidney and Transplant

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 66.7%Moderate 2 · 33.3%High 0 · 0%

Final Hb · anaemia in predialysis patients

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 288 participants
Moderate

Mean weekly epoetin dose · anaemia in predialysis patients

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 288 participants
Low

Deaths · anaemia in predialysis patients

Epoetin theta showed no clear difference in deaths compared with epoetin beta (low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 2.46 [0.29, 20.77]
1 study · 288 participants
Low

Adverse events: hypertension · anaemia in predialysis patients

Epoetin theta showed no clear difference in adverse events: hypertension compared with epoetin beta (moderate certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 0.35 [0.11, 1.08]
1 study · 288 participants
Moderate

Adverse events: RBC transfusions · anaemia in predialysis patients

Epoetin theta showed no clear difference in adverse events: RBC transfusions compared with epoetin beta (low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 1.48 [0.06, 36.1]
1 study · 288 participants
Low

Withdrawals due to adverse events · anaemia in predialysis patients

Epoetin theta showed no clear difference in adverse events: discontinuation of therapy compared with epoetin beta (low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 1.77 [0.68, 4.63]
1 study · 288 participants
Low